IMV Inc IMVIF

RE:RE:RE:RE:RE:RE:RE:RE:Looks like stock has been managed downwards the past week

[PoorOpinion]

GorgeousGeorge1 wrote: We're sitting around 10 - 20% off a few of the broker's targets which is pretty standard. Potential investors pay attention to these price targets as it's very difficult to value a clinical stage biotech. If results are good then we can expect a decent rerate across the board and the money that is sitting on the sidelines watching, should see value and jump in. I don't think we'll fall back to the $5-6 range, more likely a shot up to $12 and then settle back in the $10-11 range while we await details of the basket trial. All my opinion only of course. GL all

I think you are looking for events that derisk the story or add new sources of value. Thats why I asked a few days ago whether people thought the 3rd June results are already priced in. I tend to be cautious so I see a limit to too much upside on the 3rd June although Nasdaq+new investors+new data.could work all on it own. There is a possibility the 300mg data is so strong that it represent some  further derisking but it seems more likely that its just further confirmation of the pre-existing story (my caution, lets wait and see) . I'm not putting too much weight on the possibility that the data has a negative impact although it remains possible. Time is a factor here, most of the 300mg patients were not evaluable in Dec 2017 so this should continue to be a developing story beyond 3rd June as well, we've seen that happen with the 100mg patients recently. The best short term opportunity for upside looks like the basket trial/new partnership, lets see what it looks like but you might expect some extra value from that going into the analyst price models. Also only my limited (poor)opinion.